<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313477898</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313477898</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Papers</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>ADAMTS-13 metalloprotease abnormalities in systemic lupus erythematosus: is there a correlation with disease status?</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Klonizakis</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313477898">1</xref>
<xref ref-type="corresp" rid="corresp1-0961203313477898"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Tselios</surname><given-names>K</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313477898">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Sarantopoulos</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313477898">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Gougourellas</surname><given-names>I</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313477898">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Rouka</surname><given-names>E</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313477898">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Onufriadou</surname><given-names>Z</given-names></name>
<xref ref-type="aff" rid="aff4-0961203313477898">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kapali</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff4-0961203313477898">4</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Kyriakou</surname><given-names>D</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313477898">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Boura</surname><given-names>P</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313477898">2</xref>
</contrib>
<aff id="aff1-0961203313477898"><label>1</label>Hematology Unit, Aristotle University of Thessaloniki, Greece</aff>
<aff id="aff2-0961203313477898"><label>2</label>Clinical Immunology Unit, Aristotle University of Thessaloniki, Greece</aff>
<aff id="aff3-0961203313477898"><label>3</label>Blood Transfusion Department, University Hospital of Larissa, Greece</aff>
<aff id="aff4-0961203313477898"><label>4</label>Department of Hematology, Papageorgiou General Hospital, Greece</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0961203313477898">P Klonizakis, Hematology Unit, 2<sup>nd</sup> Department of Internal Medicine, Hippokration General Hospital, Aristotle University, 49 Konstantinoupoleos Street, Thessaloniki, Greece. Email: <email>philklon@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>443</fpage>
<lpage>452</lpage>
<history>
<date date-type="received"><day>8</day><month>3</month><year>2012</year></date>
<date date-type="accepted"><day>12</day><month>1</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2013. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>To clarify the role of ADAMTS-13 in the pathogenesis of thrombotic microangiopathy in systemic lupus erythematosus (SLE) we evaluated ADAMTS-13 profile (metalloprotease antigen levels, anti-ADAMTS-13 autoantibody levels, activity) in distinct patient groups according to disease activity, extent of cumulative tissue damage and history of antiphospholipid syndrome or end-organ damage. Forty-one lupus patients were analysed. ADAMTS-13 metalloprotease antigen levels and anti-ADAMTS-13 autoantibodies were evaluated by ELISA. ADAMTS-13 activity was measured by Fluorescence resonance energy transfer (FRET) technique. ADAMTS-13 metalloprotease antigen levels were significantly decreased in patients with Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) &gt;1 (<italic>p &lt; </italic>0.05)<italic>.</italic> ADAMTS-13 metalloprotease antigen levels also exhibited a significant inverse correlation with anti-dsDNA levels (<italic>r </italic>= −0.60, <italic>p &lt; </italic>0.05). Anti-ADAMTS-13 autoantibodies were marginally higher in patients with positive anti-dsDNA (<italic>p </italic>= 0.08). Additionally, patients with positive anti-ADAMTS-13 autoantibodies exhibited the lowest activity levels (<italic>p &lt; </italic>0.05). To our knowledge ADAMTS-13 profile in SLE has not been studied in regard to composite structured indices. The results of this study suggest that in patients with active SLE or considerable cumulative tissue damage, ADAMTS-13 levels may be decreased and anti-ADAMTS-13 autoantibodies may partially mediate this reduction. Further evaluation of ADAMTS-13 profile may explain its role in the pathogenesis of thrombotic microangiopathy in lupus patients and reveal a potential prognostic marker of microthrombotic manifestations in SLE.</p>
</abstract>
<kwd-group>
<kwd>ADAMTS-13</kwd>
<kwd>systemic lupus erythematosus</kwd>
<kwd>disease activity</kwd>
<kwd>cumulative tissue damage</kwd>
<kwd>thrombosis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313477898" sec-type="intro"><title>Introduction</title>
<p>It has been recently demonstrated that active systemic lupus erythematosus (SLE) is associated with increased risk for thrombotic thrombopenic purpura (TTP),<sup><xref ref-type="bibr" rid="bibr1-0961203313477898">1</xref></sup> a life-threatening disease characterized by thrombotic microangiopathy (TMA). The pathogenesis of idiopathic TTP (iTTP) is deficiency of ADAMTS-13 (A Disintegrin-like And Metalloproteinase with Thrombospondin type 1 motif 13) activity, in 70–80% of patients. In most cases ADAMTS 13 deficiency is due to anti-ADAMTS 13 autoantibodies formation.<sup><xref ref-type="bibr" rid="bibr2-0961203313477898">2</xref><xref ref-type="bibr" rid="bibr3-0961203313477898"/>–<xref ref-type="bibr" rid="bibr4-0961203313477898">4</xref></sup></p>
<p>ADAMTS-13 is a metalloprotease, which physiologically cleaves the ultra large von Willebrand factor (vWF) multimers secreted from endothelial Weibel-Palade bodies, in response to endothelial perturbation, activation and injury (shear stress, inflammatory cytokines including thrombin, trauma).<sup><xref ref-type="bibr" rid="bibr5-0961203313477898">5</xref></sup> The ligand for platelet adhesion at sites of vessel injury is vWF. In the absence of ADAMTS-13, ultralarge vWF multimers in conditions of high shear, can activate platelets directly leading to platelet aggregates and a consequent TMA.</p>
<p>Indeed, the relative literature concerning TTP in SLE patients is inconclusive concerning therapy and prognosis. Furthermore, ADAMTS-13 activity assessment has not been incorporated in the diagnostic approach of these patients in most studies. However, many small studies (mainly case series) support the notion that SLE-related TTP is characterized by a worse prognosis<sup><xref ref-type="bibr" rid="bibr1-0961203313477898">1</xref>,<xref ref-type="bibr" rid="bibr6-0961203313477898">6</xref></sup> Additionally, SLE disease activity and active lupus nephritis have been independently associated with a higher probability of developing TTP during the SLE course.<sup><xref ref-type="bibr" rid="bibr1-0961203313477898">1</xref></sup> Based on these data, it may be suggested that TTP in SLE is a more complicated condition than iTTP and these differences can be attributed to the unique and composite mechanisms of thrombotic microangiopathy in SLE.<sup><xref ref-type="bibr" rid="bibr7-0961203313477898">7</xref></sup></p>
<p>Recent studies suggest that the inflammatory, auto-reactive and prothrombotic environment of SLE may influence the balance between ADAMTS-13 and vWF, thus resulting in an unstable and potentially fatal equilibrium.<sup><xref ref-type="bibr" rid="bibr8-0961203313477898">8</xref><xref ref-type="bibr" rid="bibr9-0961203313477898"/><xref ref-type="bibr" rid="bibr10-0961203313477898"/><xref ref-type="bibr" rid="bibr11-0961203313477898"/><xref ref-type="bibr" rid="bibr12-0961203313477898"/>–<xref ref-type="bibr" rid="bibr13-0961203313477898">13</xref></sup> It has also been postulated that, in lupus patients with TMA manifestations, abnormalities of ADAMTS-13 may be attributed to additional mechanisms, other than inhibitor formation.<sup><xref ref-type="bibr" rid="bibr7-0961203313477898">7</xref>,<xref ref-type="bibr" rid="bibr14-0961203313477898">14</xref></sup></p>
<p>In the present study, we evaluated if the abnormalities of ADAMTS-13 in SLE are related to disease activity and extent of cumulative tissue damage. For this reason we assessed the profile of ADAMTS-13 (metalloprotease levels, anti-ADAMTS-13 autoantibody levels, metalloprotease activity) in regard to disease activity, extent of cumulative tissue damage and history of antiphospholipid syndrome or end-organ damage.</p>
</sec>
<sec id="sec2-0961203313477898" sec-type="methods"><title>Methods</title>
<sec id="sec3-0961203313477898" sec-type="subjects"><title>Patients</title>
<p>The Human Ethics Review Committee of the Aristotle University of Thessaloniki approved the study protocol and informed consent was obtained from each patient. We retrospectively evaluated 41 consecutive patients, from a registry of 200 lupus patients followed at the Clinical Immunology Unit, 2nd Department of Internal Medicine, Hippokration General Hospital, Aristotle University of Thessaloniki. All registered SLE patients fulfilled the ACR criteria<sup><xref ref-type="bibr" rid="bibr15-0961203313477898">15</xref>,<xref ref-type="bibr" rid="bibr16-0961203313477898">16</xref></sup> and were evaluated regularly at six-month intervals. During each visit, demographic, clinical and laboratory parameters were updated in an electronic database. SLE-specific records include among others: the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score, the SLICC/ACR Damage Index Score (DIS), the disease duration and the history of antiphospholipid syndrome (APS) or end-organ damage. Blood samples were taken from each patient and separated into two different plastic tubes with or without anticoagulant for plasma and serum isolation respectively. Blood samples containing anticoagulant (0.5 ml of 3.8% sodium citrate) were centrifuged twice at 5000 × g and plasma was isolated within two hours after venipuncture. Serum and plasma samples taken from each patient were stored in aliquots at −70 <sup>°</sup>C for evaluation of ADAMTS-13 profile.</p>
</sec>
<sec id="sec4-0961203313477898"><title>ADAMTS-13 antigen levels</title>
<p>Metalloprotease antigen levels were measured by commercial ELISA (IMUBIND ADAMTS-13 ELISA Product No 813, American Diagnostica Inc.) according to the manufacturer’s instructions, The 95% reference range for ADAMTS-13 normal antigen values was 168–912 ng/ml (mean ± standard deviation (SD), 540 ± 190 ng/ml) and was established in the Hematology Laboratory of Papageorgiou Hospital, using plasma samples of healthy individuals (<italic>n </italic>= 20). The intra-and inter-assay coefficients of variation were found to be 3.8% and 7.1%, respectively.</p>
</sec>
<sec id="sec5-0961203313477898"><title>Anti-ADAMTS-13 autoantibodies</title>
<p>Frozen serum samples were sent to the Hematology Laboratory of the University Hospital of Larissa. Special equipment containing cardice was used for transportation. Detection of autoantibodies (IgG) against ADAMTS-13 protease was performed by ELISA (TECHNOZYM ADAMTS-13 INH ELISA test by Technoclone GmbH; Brunner Str. 59/5,1230 Vienna, Austria), following the manufacturer’s instructions. In brief, the samples were added to micro-wells coated with recombinant ADAMTS-13. If present, anti-ADAMTS-13 autoantibodies preferentially bind to the cysteine-rich spacer domains of ADAMTS-13.<sup><xref ref-type="bibr" rid="bibr17-0961203313477898">17</xref></sup> After incubation at room temperature, IgG human autoantibodies bound to ADAMTS-13 were detected using a horseradish peroxidase (HRP)-conjugated anti-human IgG polyclonal antibody. After the chromogenic substrate tetramethylbenzidine (TMB) was added, binding was visualized as a color product determined by photometry. The values of optical absorption were compared with a standard curve generated from five calibrators of known anti-ADAMTS-13 IgG titer included in the commercial kit. Each calibrator, control and sample was tested in duplicate. The validity of the test was checked on the basis of the calculated control values and the deviation between repeated measurements was &lt;4%. Results were interpreted as: negative samples &lt;12 units/ml, borderline samples 12–15 units/ml and positive samples &gt;15 units/ml. Determination of these values were made after evaluation of 100 healthy blood donors: each patient sample was evaluated for two times.</p>
</sec>
<sec id="sec6-0961203313477898"><title>ADAMTS-13 activity</title>
<p>Frozen plasma samples were sent to the Hematology Laboratory of the University Hospital of Larissa, as described above. Metalloprotease activity quantitative measurement was performed with the ADAMTS-13 Activity Assay® (GTi diagnostics, 20925 Crossroads Circle, Suite 200, Waukesha, Wisconsin, USA). Briefly, the method is based on the detection of small fluorescent fragments of vWF, generated from cleavage of synthetic vWF by the ADAMTS-13 protease in plasma samples (FRET). All procedures were performed according to the manufacturer’s instructions in a controlled area at 22–25 °C since the enzyme substrate reaction is temperature sensitive. Frozen plasma was thawed rapidly at 37 °C, stored at 2–8 °C and assayed within four hours. Calibrators, controls and samples were tested in duplicate using kits with the same batch number. Standard curve was constructed by plotting the mean fluorescence value for each of the five calibrators versus its corresponding concentration of ADAMTS-13 activity. The laboratory normal range was calculated based on measurements in 100 healthy individuals. Plasma samples with calculated ADAMTS-13 activity equal and/or greater than 65% were reported as normal. We have also tested 76 samples from TTP patients at clinical relapse and the ADAMTS-13 activity was found lower than 5% in all cases which is diagnostic for the disease.<sup><xref ref-type="bibr" rid="bibr4-0961203313477898">4</xref></sup> In our hands, the reproducibility of the assay using this commercial kit yielded a mean within assay coefficient of variation of 4.2% (intra-CV) and a mean between-assay coefficient of variation of 8.3% (inter-CV).</p>
</sec>
<sec id="sec7-0961203313477898"><title>Disease activity and extent of tissue damage markers</title>
<p>To evaluate the ADAMTS-13 profile in regard to disease activity and extent of tissue damage, we subdivided patients according to composite structured indices (SLEDAI, SLICC/ACR) and other clinical and laboratory parameters. The same physician assessed all patients on the SLEDAI and SLICC/ACR, according to initial descriptions.<sup><xref ref-type="bibr" rid="bibr18-0961203313477898">18</xref>,<xref ref-type="bibr" rid="bibr19-0961203313477898">19</xref></sup> Regarding SLEDAI, values between 1–5 were considered as mild disease activity, whereas higher values (&gt;5) were considered as moderate or severe disease activity, usually indicating the need of additional immunosuppressive therapy.<sup><xref ref-type="bibr" rid="bibr20-0961203313477898">20</xref>,<xref ref-type="bibr" rid="bibr21-0961203313477898">21</xref></sup> Additionally, patients were subdivided according to anti-dsDNA positivity, a parameter associated with disease activity and lupus nephritis.<sup><xref ref-type="bibr" rid="bibr22-0961203313477898">22</xref>,<xref ref-type="bibr" rid="bibr23-0961203313477898">23</xref></sup> Anti-dsDNA antibodies were assessed by indirect immunofluorescence method on a <italic>Crithidia luciliae</italic> substrate. The anti-dsDNA antibodies were further evaluated in all positive samples by ELISA (Genesis, Cambridge, UK) according to the manufacturer’s instructions. Concerning tissue damage extent, patients were subdivided in three groups with minimal (SLICC/ACR<italic> </italic>= 0), moderate (SCLICC/ACR<italic> </italic>= 1) and maximal cumulative tissue damage (SLICC/ACR&gt;1).<sup><xref ref-type="bibr" rid="bibr24-0961203313477898">24</xref></sup> Further evaluation was performed regarding the history of APS or end-organ damage. APS was defined according to the updated international consensus classification criteria.<sup><xref ref-type="bibr" rid="bibr25-0961203313477898">25</xref></sup> and laboratory assessment included the detection of anti-cardiolipin (aCL) antibodies, anti-β<sub>2</sub> glucoprotein I (β<sub>2</sub>GPI) antibodies and lupus anticoagulant (LAC) antibodies.</p>
</sec>
<sec id="sec8-0961203313477898"><title>Statistical analysis</title>
<p>ADAMTS-13 profile was analyzed in regard to the clinical and laboratory parameters for each patient. All continuous variables were tested for normal distribution by the Shapiro-Wilk test. The student’s <italic>t</italic>-test or Mann-Whitney U-test was used to assess group differences in ADAMTS-13 profile on normally or non-normally distributed numerical variables respectively. Associations between continuous variables were tested by Pearson’s correlation coefficient test and Spearman Rank Correlation. A <italic>p</italic> value &lt;0.05 was considered to be statistically significant, whereas <italic>p</italic> values between 0.05–0.08 were considered as marginally significant. All <italic>p</italic> values were two-tailed. The SPSS for Windows, version 11.5 (SPSS, Chicago, Illinois, USA), software package was used for this analysis.</p>
</sec>
</sec>
<sec id="sec9-0961203313477898" sec-type="results"><title>Results</title>
<p>Demographic, clinical and laboratory data of all patient groups are shown in Tables <xref ref-type="table" rid="table1-0961203313477898">1</xref> and <xref ref-type="table" rid="table2-0961203313477898">2</xref>. Immune-active ADAMTS-13 metalloprotease was evaluated in 33/41 patients. ADAMTS-13 levels ranged from 177–789 ng/ml (median: 526 ng/ml) and the lower and upper quartiles were 351 ng/ml and 629 ng/ml respectively.
<table-wrap id="table1-0961203313477898" position="float"><label>Table 1</label><caption><p>Demographic, clinical data and ADAMTS-13 profile in group of patients according to disease activity (<italic>n </italic>= 41)</p></caption>
<graphic alternate-form-of="table1-0961203313477898" xlink:href="10.1177_0961203313477898-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th colspan="5">Disease activity</th>
</tr>
<tr>
<td colspan="2">SLEDAI</td>
<td colspan="2">Anti-dsDNA</td>
</tr>
<tr><th>Disease status</th>
<th>≤5</th>
<th>&gt;5</th>
<th>negative</th>
<th>positive</th>
<th><italic>p</italic> value</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Patients (<italic>n</italic>)</td>
<td>28</td>
<td>13</td>
<td>27</td>
<td>14</td>
</tr>
<tr>
<td>Male/female</td>
<td>2/26</td>
<td>3/10</td>
<td>3/24</td>
<td>2/12</td>
<td>NS</td>
</tr>
<tr>
<td>Median age</td>
<td>42 (23–74)</td>
<td>45 (27–78)</td>
<td>48 (27–78)</td>
<td>36 (23–67)</td>
<td>NS</td>
</tr>
<tr>
<td> ≤45years</td>
<td>16</td>
<td>7</td>
<td>11</td>
<td>12</td>
<td>NS</td>
</tr>
<tr>
<td> &gt;45years</td>
<td>12</td>
<td>6</td>
<td>16</td>
<td>2</td>
<td>NS</td>
</tr>
<tr>
<td>Disease duration, months</td>
<td>114 (6–360)</td>
<td>120 (6–360)</td>
<td>120 (12–360)</td>
<td>62 (6–240)</td>
<td>NS</td>
</tr>
<tr>
<td>History of renal disease</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>NS</td>
</tr>
<tr>
<td>History of CNS disease</td>
<td>4</td>
<td>4</td>
<td>6</td>
<td>2</td>
<td>NS</td>
</tr>
<tr>
<td colspan="6">ADAMTS-13 profile</td>
</tr>
<tr>
<td>ADAMTS-13 levels, ng/ml</td>
<td>510 (177–712) <italic>n </italic>= 22</td>
<td>578 (325–789) <italic>n </italic>= 11</td>
<td>503 (177–789) <italic>n </italic>= 21</td>
<td>537 (216–712) <italic>n </italic>= 12</td>
<td>NS</td>
</tr>
<tr>
<td>Anti-ADAMTS-13, IU/ml</td>
<td>7 (0–34) <italic>n </italic>= 26</td>
<td>6 (2–31) <italic>n </italic>= 13</td>
<td>6 (0–34) <italic>n </italic>= 26</td>
<td>10 (2–31) <italic>n </italic>= 13</td>
<td>0.08 <sup><xref ref-type="table-fn" rid="table-fn2-0961203313477898">a</xref></sup></td>
</tr>
<tr>
<td>ADAMTS-13 activity, %</td>
<td>150 (29–255) <italic>n </italic>= 20</td>
<td>136 (92–188) <italic>n </italic>= 8</td>
<td>148 (29–255) <italic>n </italic>= 18</td>
<td>136 (92–236) <italic>n </italic>= 10</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313477898"><p>CNS: central nervous system; NS: not significant; SLEDAI: Systemic Lupus Erythematosus Disease Index.</p></fn>
<fn id="table-fn2-0961203313477898"><label>a</label><p>p<italic> </italic>= 0,08 between positive and negative anti-dsDNA.</p></fn></table-wrap-foot>
</table-wrap>
<table-wrap id="table2-0961203313477898" position="float"><label>Table 2</label><caption><p>Demographic, clinical data and ADAMTS-13 profile in patient groups according to extent of cumulative tissue damage and history of end-organ damage or antiphospholipid syndrome (APS) (<italic>n </italic>= 41)</p></caption>
<graphic alternate-form-of="table2-0961203313477898" xlink:href="10.1177_0961203313477898-table2.tif"/>
<table frame="hsides">
<tbody align="left">
<tr>
<td colspan="3">Cumulative tissue damage</td>
<td colspan="2">End-organ damage</td>
<td colspan="2">APS</td>
</tr>
<tr>
<td colspan="3">SLICC/ACR DIS</td>
</tr>
<tr>
<td>Disease status</td>
<td>0</td>
<td>1</td>
<td>&gt;1</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td><italic>p</italic> value</td>
</tr>
<tr>
<td>Patients (<italic>n</italic>)</td>
<td>17</td>
<td>12</td>
<td>12</td>
<td>28</td>
<td>13</td>
<td>30</td>
<td>11</td>
</tr>
<tr>
<td>Male/female</td>
<td>3/14</td>
<td>1/11</td>
<td>1/11</td>
<td>1/27</td>
<td>4/9</td>
<td>3/27</td>
<td>2/9</td>
<td>NS</td>
</tr>
<tr>
<td>Median age, years</td>
<td>36 (23–59)</td>
<td>51 (27–67)</td>
<td>52 (29–49)</td>
<td>46 (23–78)</td>
<td>43 (24–58)</td>
<td>45 (23–78)</td>
<td>45 (27–74)</td>
<td>NS</td>
</tr>
<tr>
<td> ≤45years</td>
<td>15</td>
<td>4</td>
<td>4</td>
<td>14</td>
<td>9</td>
<td>17</td>
<td>6</td>
<td>NS</td>
</tr>
<tr>
<td> &gt;45years</td>
<td>2</td>
<td>8</td>
<td>8</td>
<td>14</td>
<td>4</td>
<td>13</td>
<td>5</td>
<td>NS</td>
</tr>
<tr>
<td>Disease duration, months</td>
<td>36 (6–144)</td>
<td>150 (12–360)</td>
<td>196 (12–360)</td>
<td>114 (6–360)</td>
<td>144 (6–360)</td>
<td>114 (6–360)</td>
<td>156 (12–360)</td>
<td>&lt;0.001 <sup><xref ref-type="table-fn" rid="table-fn4-0961203313477898">a</xref>,<xref ref-type="table-fn" rid="table-fn5-0961203313477898">b</xref></sup></td>
</tr>
<tr>
<td>History of renal disease</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>–</td>
<td>6</td>
<td>4</td>
<td>2</td>
<td>NS</td>
</tr>
<tr>
<td>History of CNS disease</td>
<td>1</td>
<td>4</td>
<td>3</td>
<td>–</td>
<td>8</td>
<td>2</td>
<td>6</td>
<td>NS</td>
</tr>
<tr>
<td colspan="9"><italic>ADAMTS-13 profile</italic></td>
</tr>
<tr>
<td>Metalloprotease, ng/ml</td>
<td>584 (177–708) <italic>n </italic>= 12</td>
<td>562 (297–789) <italic>n </italic>= 11</td>
<td>391 (216–712) <italic>n </italic>= 10</td>
<td>526 (285–789) <italic>n </italic>= 23</td>
<td>541 (177–657) <italic>n </italic>= 10</td>
<td>533 (216–712) <italic>n </italic>= 24</td>
<td>524 (177–789) <italic>n </italic>= 9</td>
<td>&lt;0.05 <sup><xref ref-type="table-fn" rid="table-fn6-0961203313477898">c</xref></sup></td>
</tr>
<tr>
<td>Anti-ADAMTS-13, IU/ml</td>
<td>8 (0–31) <italic>n </italic>= 15</td>
<td>9 (2–34) <italic>n </italic>= 12</td>
<td>6 (3–20) <italic>n </italic>= 12</td>
<td>6 (0–20) <italic>n </italic>= 26</td>
<td>9 (0–34) <italic>n </italic>= 13</td>
<td>6 (0–34) <italic>n </italic>= 28</td>
<td>9 (0–22) <italic>n </italic>= 11</td>
<td>NS</td>
</tr>
<tr>
<td>Activity, %</td>
<td>144 (103–188) <italic>n </italic>= 12</td>
<td>149 (92–188) <italic>n </italic>= 9</td>
<td>132 (29–255) <italic>n </italic>= 7</td>
<td>146 (29–188) <italic>n </italic>= 17</td>
<td>140 (92–255) <italic>n </italic>= 11</td>
<td>151 (94–255) <italic>n </italic>= 20</td>
<td>131 (29–188) <italic>n </italic>= 8</td>
<td>NS</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0961203313477898"><p>CNS: central nervous system; DIS: Damage Index Score; SLICC/ACR: Systemic Lupus International Collaborative Clinics/American College of Rheumatology.</p></fn>
<fn id="table-fn4-0961203313477898"><label>a</label><p><italic>p &lt; </italic>0,001 between SLICC/ACR DIS<italic> </italic>= 1 and SLICC/ACR DIS<italic> </italic>= 0.</p></fn>
<fn id="table-fn5-0961203313477898"><label>b</label><p><italic>p &lt; </italic>0,001 between SLICC/ACR DIS &gt;1 and SLICC/ACR DIS<italic> </italic>= 0.</p></fn>
<fn id="table-fn6-0961203313477898"><label>c</label><p><italic>p &lt; </italic>0.05 between SLICC/ACR DIS &gt;1 and SLICC/ACR DIS<italic> </italic>= 0.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Anti-ADAMTS-13 autoantibodies were detected in positive titers in 7/40 patients (17.5%), with autoantibody levels ranging from 16 to 31 IU/ml, whereas borderline titers were detected in 3/40 patients (7.5%).</p>
<p>ADAMTS-13 activity was evaluated in 31/41 patients: activity ranged from 29–255% (median: 144%).</p>
<sec id="sec10-0961203313477898"><title>Comparison of ADAMTS-13 levels and activity in patients with positive or negative anti-ADAMTS-13 autoantibody titers</title>
<p>There was no significant difference of ADAMTS-13 levels between patients with positive or negative anti-ADAMTS-13 autoantibodies (446 ± 192 vs 512 ± 150, <italic>p </italic>= 0.4). ADAMTS-13 activity was significantly lower in patients with positive anti-ADAMTS-13 autoantibodies than in patients with a negative titer (95% (29–176) vs 149% (105–255), <italic>p &lt; </italic>0.05; (<xref ref-type="fig" rid="fig1-0961203313477898">Figure 1</xref>). However, only one patient with positive anti-ADAMTS-13 autoantibodies exhibited a metalloprotease activity (29%) below normal levels (&lt;65%). As shown in <xref ref-type="table" rid="table3-0961203313477898">Table 3</xref>, this unique patient also exhibited a metalloprotease level (285 ng/ml) that was below the lower quartile of the distribution of ADAMTS-13 in all patients.
<fig id="fig1-0961203313477898" position="float"><label>Figure 1</label><caption><p>Comparison of ADAMTS-13 activity in patients with negative or positive anti-ADAMTS-13 autoantibodies.</p></caption><graphic xlink:href="10.1177_0961203313477898-fig1.tif"/>
</fig>
<table-wrap id="table3-0961203313477898" position="float"><label>Table 3</label><caption><p>Characteristics of 3/41 patients exhibiting the lowest ADAMTS‐13 protease levels</p></caption>
<graphic alternate-form-of="table3-0961203313477898" xlink:href="10.1177_0961203313477898-table3.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Patient 1</th>
<th>Patient 2</th>
<th>Patient 3</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Age/sex</td>
<td>36/M</td>
<td>29/F</td>
<td>47/F</td>
</tr>
<tr>
<td>APS</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>End-organ damage</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>SLEDAI</td>
<td>2</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>SLICC/ACR DIS</td>
<td>0</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>αντι-dsDNA</td>
<td>−</td>
<td>+</td>
<td>−</td>
</tr>
<tr>
<td>ADAMTS-13, ng/ml</td>
<td>177</td>
<td>216</td>
<td>285</td>
</tr>
<tr>
<td>Anti-ADAMTS-13, IU/ml</td>
<td>0 (negative)</td>
<td>14 (borderline)</td>
<td>20 (positive)</td>
</tr>
<tr>
<td>ADAMTS-13 activity</td>
<td>105%</td>
<td>236%</td>
<td>29%</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0961203313477898"><p>APS: antiphospholipid syndrome; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SLICC/ACR: Systemic Lupus International Collaborative Clinics/American College of Rheumatology.</p></fn></table-wrap-foot>
</table-wrap></p>
</sec>
<sec id="sec11-0961203313477898"><title>ADAMTS-13 profile in regard to extent of cumulative tissue damage and disease activity</title>
<p>Analysis of ADAMTS-13 profile in each study group are shown in Tables <xref ref-type="table" rid="table1-0961203313477898">1</xref> and <xref ref-type="table" rid="table2-0961203313477898">2</xref>. Concerning the subgroups divided according to SLICC/ACR, metalloprotease levels were significantly lower in patients with maximal cumulative tissue damage compared to patients with minimal damage (391 ng/ml (216–712) vs 584 ng/ml (177–708), <italic>p &lt; </italic>0.05 (<xref ref-type="fig" rid="fig2-0961203313477898">Figure 2</xref>). There were no significant differences in ADAMTS-13 levels between patients with moderate and minimal cumulative tissue damage.
<fig id="fig2-0961203313477898" position="float"><label>Figure 2</label><caption><p>Comparison of ADAMTS-13 metalloprotease in patients without cumulative damage (SLICC/ACR DIS<italic> </italic>= 0) or extended cumulative damage (SLICC/ACR DIS &gt;1).</p></caption><graphic xlink:href="10.1177_0961203313477898-fig2.tif"/>
</fig></p>
<p>Analysis in regard to history of APS or end-organ damage did not reveal any significant differences in ADAMTS-13 profile (<xref ref-type="table" rid="table2-0961203313477898">Table 2</xref>).</p>
<p>Further analysis of three patients who exhibited the lowest levels of ADAMTS-13 showed that end-organ damage was a common finding (<xref ref-type="table" rid="table3-0961203313477898">Table 3</xref>). Moreover, one of these three patients exhibited an extremely low activity (29%) combined with an increased SLICC/ACR (<italic> </italic>= 2) (<xref ref-type="table" rid="table3-0961203313477898">Table 3</xref>).</p>
<p>Regarding disease activity, there were no significant differences in ADAMTS-13 profile between patients with a low (≤5) or a high (&gt; 5) SLEDAI (<xref ref-type="table" rid="table1-0961203313477898">Table 1</xref>). Additional analysis showed a weak positive correlation of SLEDAI with anti-ADAMTS-13 autoantibody levels (<italic>r </italic>= 0.3, <italic>p &lt; </italic>0.05) but no correlation was observed with ADAMTS-13 protease levels or activity.</p>
<p>Although there was no significant difference in metalloprotease levels between patients with a positive or a negative anti-dsDNA titer, further analysis of patients with a positive anti-dsDNA titer showed a significant inverse correlation between ADAMTS-13 and anti-dsDNA autoantibody levels (<italic>r </italic>= −0.6, <italic>p &lt; </italic>0.05 (<xref ref-type="fig" rid="fig3-0961203313477898">Figure 3</xref>)). Furthermore, there was a marginally significant difference in anti-ADAMTS-13 autoantibody levels between positive and negative anti-dsDNA patients (10 (2–31) vs 6 (0–34), <italic>p </italic>= 0.08 (<xref ref-type="fig" rid="fig4-0961203313477898">Figure 4</xref>)).
<fig id="fig3-0961203313477898" position="float"><label>Figure 3</label><caption><p>Correlation of anti-dsDNA autoantibodies with ADAMTS-13 metalloprotease.</p></caption><graphic xlink:href="10.1177_0961203313477898-fig3.tif"/>
</fig>
<fig id="fig4-0961203313477898" position="float"><label>Figure 4</label><caption><p>Comparison of anti-ADAMTS-13 autoantibody levels in patients with negative or positive anti-dsDNA autoantibodies titer.</p></caption><graphic xlink:href="10.1177_0961203313477898-fig4.tif"/>
</fig></p>
</sec>
</sec>
<sec id="sec12-0961203313477898" sec-type="discussion"><title>Discussion</title>
<p>ADAMTS-13 abnormalities have been described in SLE: however, to our knowledge there are no data to demonstrate its correlation to disease activity, extent of cumulative tissue damage and other specific disease parameters. The significantly lower ADAMTS-13 levels in patients with considerable cumulative tissue damage (SLICC/ACR &gt;1), may suggest that mechanisms of TMA could be associated with subclinical organ damage in SLE. Moreover, in anti-dsDNA positive patients, the significant correlation of low protease with high anti-dsDNA levels may implicate a prothrombotic state in lupus patients, who exhibit an increased possibility of disease flare.<sup><xref ref-type="bibr" rid="bibr18-0961203313477898">18</xref>,<xref ref-type="bibr" rid="bibr19-0961203313477898">19</xref></sup> Anti-ADAMTS-13 autoantibodies were correlated with a significant reduction of ADAMTS-13 activity. This finding might imply that the presence of anti-ADAMTS-13 autoantibodies could be responsible for the decrease in ADAMTS-13 activity.</p>
<p>The abnormalities concerning ADAMTS-13 and its inhibitors, like autoantibodies, have been studied in SLE and in other connective tissue diseases characterized by TMA manifestations.<sup><xref ref-type="bibr" rid="bibr14-0961203313477898">14</xref>,<xref ref-type="bibr" rid="bibr26-0961203313477898">26</xref><xref ref-type="bibr" rid="bibr27-0961203313477898"/>–<xref ref-type="bibr" rid="bibr28-0961203313477898">28</xref></sup> However, there is no study that evaluates ADAMTS-13 profile in regard to specific clinical and laboratory parameters of SLE.</p>
<p>Liu <italic>et al.</italic> showed that ADAMTS-13 levels were increased in SLE patients and concluded that this could be explained as a response to increased vWF levels measured in the same group of patients. Moreover, they found that ADAMTS-13 activity was moderately decreased (20–50%) but they did not detect any anti-ADAMTS-13 inhibitors.<sup><xref ref-type="bibr" rid="bibr26-0961203313477898">26</xref></sup> Mannucci <italic>et al.</italic> concluded that plasma levels of ADAMTS-13 may be decreased in connective tissue diseases but there are no autoantibodies inactivating the protease activity.<sup><xref ref-type="bibr" rid="bibr28-0961203313477898">28</xref></sup> Rieger <italic>et al.</italic> also evaluated ADAMTS-13 activity in SLE patients and found that activity levels were normal or moderately decreased. They also detected IgG type anti-ADAMTS-13 autoantibodies in 13% of SLE patients but they did not find any significant correlation between autoantibodies and ADAMTS-13 activity.<sup><xref ref-type="bibr" rid="bibr27-0961203313477898">27</xref></sup> Any controversial conclusions may be partially interpreted by differences in laboratory techiques and diversity of disease status.</p>
<p>It is suggested that in SLE, the inflammatory, auto-reactive and prothrombotic environment may explain any ADAMTS-13 abnormalities reported in previous studies. An increase in vWF large multimers, mediated by inflammatory cytokines, shear stress or vascular injury, may initially cause an increase in ADAMTS-13 activity. However, in cases of rapid and massive vWF multimer production, this may be followed by decreased and/or deficient ADAMTS-13 activity due to consumption.<sup><xref ref-type="bibr" rid="bibr4-0961203313477898">4</xref>,<xref ref-type="bibr" rid="bibr7-0961203313477898">7</xref>,<xref ref-type="bibr" rid="bibr14-0961203313477898">14</xref></sup> Another study reported that the prothrombotic state of APS may be partially attributed to ADAMTS-13 dysfunction.<sup><xref ref-type="bibr" rid="bibr29-0961203313477898">29</xref></sup></p>
<p>Our study is in agreement with Matsuyama <italic>et al.</italic> who analysed the clinical characteristics and the ADAMTS-13 abnormalities in patients with autoimmune disease and TMA.<sup><xref ref-type="bibr" rid="bibr14-0961203313477898">14</xref></sup> They found that ADAMTS-13 activity was significantly decreased in these patients compared to healthy individuals. They concluded that ADAMTS-13 may be useful as a prognostic factor, since patients with severe deficiency of ADAMTS-13 activity appeared to have better therapeutic outcomes compared to the other groups with normal or moderately reduced activity. Additionally, in patients with severely deficient ADAMTS-13 activity, IgG anti-ADAMTS-13 autoantibodies were detected in 86%, whereas in patients with moderately deficient ADAMTS-13 activity, IgG anti-ADAMTS-13 autoantibodies were detected in only 5%.</p>
<p>Moreover, we have studied the possible association of ADAMTS-13 activity, levels and autoantibodies, with SLE disease activity and extent of cumulative tissue damage. Our findings imply that ADAMTS-13, may participate in the pathogenetic process of TMA in SLE.</p>
<p>In the present study, ADAMTS-13 metalloprotease and activity levels were found to be decreased but not reaching levels of &lt;5% which occur with TTP. It could be hypothesized that, in SLE, decreased ADAMTS-13 protease or activity levels may express a potentially abnormal equilibrium between ADAMTS-13 and vWF, thus making these certain patients more prone to develop TMA. The chronic inflammatory microenvironment of SLE and any increase in disease activity or extent of tissue damage may adversely affect this equilibrium by multiple mechanisms.<sup><xref ref-type="bibr" rid="bibr7-0961203313477898">7</xref></sup> On the one hand, vasculitis and shear stress can promote the release of vWF multimers from endothelial cells;<sup><xref ref-type="bibr" rid="bibr5-0961203313477898">5</xref>,<xref ref-type="bibr" rid="bibr14-0961203313477898">14</xref></sup> on the other hand inflammatory cytokines, which inhibit ADAMTS-13 synthesis in the liver<sup><xref ref-type="bibr" rid="bibr30-0961203313477898">30</xref></sup> or the production of anti-ADAMTS-13 autoantibodies,<sup><xref ref-type="bibr" rid="bibr4-0961203313477898">4</xref></sup> may induce ADAMTS-13 decrease. In this context, moderate changes in ADAMTS-13 levels may become clinically significant in SLE patients.</p>
<p>On this rationale, our findings support the clinical value of ADAMTS-13 as a future prognostic factor for TMA in SLE patients, under an unstable, inflammatory, prothrombotic state. This is in agreement with the findings of Kwok <italic>et al.</italic>, showing that increased SLE activity is a risk factor for TTP<sup><xref ref-type="bibr" rid="bibr1-0961203313477898">1</xref></sup> although this hypothesis has been disputed by others.<sup><xref ref-type="bibr" rid="bibr31-0961203313477898">31</xref></sup></p>
<p>Limitations of the present study are the small number of patients enrolled at the moment, as well as the lack of re-evaluation in phases of different disease activity. Moreover, SLEDAI is used for a short-term clinical assessment and may not capture ongoing organ damage. Additionally, it is not known if the inverse correlation between anti-dsDNA antibodies and ADAMTS-13 levels may represent a predisposition to TMA manifestations along with disease flare. Nevertheless, the quite clear association of decreased ADAMTS-13 levels with considerable cumulative tissue damage, as expressed by SLICC/ACR, is likely to represent silent organ damage, possibly mediated by TMA mechanism.</p>
<p>In conclusion, we suggest that interpretation of ADAMTS-13 levels, activity and autoantibodies should be individualized according to SLE disease status. To our knowledge, this is the first study that associated increased disease activity and extensive cumulative damage with decreased ADAMTS-13 levels in SLE patients. The extension of this study may provide additional evidence regarding the dynamics of ADAMTS-13 in the pathophysiology of TMA in SLE and may also reveal a potential prognostic marker of lupus-related thrombotic manifestations.</p>
</sec>
</body>
<back>
<sec id="sec13-0961203313477898"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec14-0961203313477898"><title>Conflicts of interest</title>
<p>None declared.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313477898"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwok</surname><given-names>S</given-names></name><name><surname>Ju</surname><given-names>J</given-names></name><name><surname>Cho</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>H</given-names></name><name><surname>Park</surname><given-names>S</given-names></name></person-group>. <article-title>Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: risk factors and clinical outcome: A single centre study</article-title>. <source>Lupus</source> <year>2009</year>; <volume>18</volume>: <fpage>16</fpage>–<lpage>21</lpage>.</citation></ref>
<ref id="bibr2-0961203313477898"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sadler</surname><given-names>JE</given-names></name><name><surname>Moake</surname><given-names>JL</given-names></name><name><surname>Miyata</surname><given-names>T</given-names></name><name><surname>George</surname><given-names>JN</given-names></name></person-group>. <article-title>Recent advances in thrombotic thrombocytopenic purpura</article-title>. <source>Hematology Am Soc Hematol Educ Program</source> <year>2004</year>; <fpage>407</fpage>–<lpage>423</lpage>.</citation></ref>
<ref id="bibr3-0961203313477898"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>XL</given-names></name><name><surname>Kaufman</surname><given-names>RM</given-names></name><name><surname>Goodnough</surname><given-names>LT</given-names></name><name><surname>Sadler</surname><given-names>JE</given-names></name></person-group>. <article-title>Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura</article-title>. <source>Blood</source> <year>2004</year>; <volume>103</volume>: <fpage>4043</fpage>–<lpage>4049</lpage>.</citation></ref>
<ref id="bibr4-0961203313477898"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>H-M</given-names></name></person-group>. <article-title>Pathophysiology of thrombotic thrombocytopenic purpura</article-title>. <source>Int J Hematol</source> <year>2010</year>; <volume>91</volume>: <fpage>1</fpage>–<lpage>19</lpage>.</citation></ref>
<ref id="bibr5-0961203313477898"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lowenstein</surname><given-names>CJ</given-names></name><name><surname>Morrell</surname><given-names>CN</given-names></name><name><surname>Yamakuchi</surname><given-names>M</given-names></name></person-group>. <article-title>Regulation of Weibel-Palade body exocytosis</article-title>. <source>Trends Cardiovasc Med</source> <year>2005</year>; <volume>15</volume>: <fpage>302</fpage>–<lpage>308</lpage>.</citation></ref>
<ref id="bibr6-0961203313477898"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Letchumanan</surname><given-names>P</given-names></name><name><surname>Ng</surname><given-names>H-J</given-names></name><name><surname>Lee</surname><given-names>L-H</given-names></name><name><surname>Thumboo</surname><given-names>J</given-names></name></person-group>. <article-title>A comparison of thrombotic thrombocytopenic purpura in an inception cohort of patients with and without systemic lupus erythematosus</article-title>. <source>Rheumatology (Oxford)</source> <year>2009</year>; <volume>48</volume>: <fpage>399</fpage>–<lpage>403</lpage>.</citation></ref>
<ref id="bibr7-0961203313477898"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lansigan</surname><given-names>F</given-names></name><name><surname>Isufi</surname><given-names>I</given-names></name><name><surname>Tagoe</surname><given-names>CE</given-names></name></person-group>. <article-title>Microangiopathic haemolytic anaemia resembling thrombotic thrombocytopenic purpura in systemic lupus erythematosus: The role of ADAMTS13</article-title>. <source>Rheumatology</source> <year>2010</year>; <volume>50</volume>: <fpage>824</fpage>–<lpage>829</lpage>.</citation></ref>
<ref id="bibr8-0961203313477898"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Al-Awadhi</surname><given-names>AM</given-names></name><name><surname>Jadaon</surname><given-names>MM</given-names></name><name><surname>Al-Jafar</surname><given-names>HA</given-names></name><name><surname>Al-Wazzan</surname><given-names>HJ</given-names></name></person-group>. <article-title>ADAMTS-13 antigen and activity levels in thrombocytopenic disorders including thrombotic thrombocytopenic purpura in Kuwait</article-title>. <source>Acta Haem</source> <year>2011</year>; <volume>125</volume>: <fpage>160</fpage>–<lpage>166</lpage>.</citation></ref>
<ref id="bibr9-0961203313477898"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lancellotti</surname><given-names>S</given-names></name><name><surname>De Filippis</surname><given-names>V</given-names></name><name><surname>Pozzi</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: A new prothrombotic mechanism in diseases associated with oxidative stress</article-title>. <source>Free Radic Biol Med</source> <year>2010</year>; <volume>48</volume>: <fpage>446</fpage>–<lpage>456</lpage>.</citation></ref>
<ref id="bibr10-0961203313477898"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Oxidative modification of von Willebrand factor by neutrophil oxidants inhibits its cleavage by ADAMTS13</article-title>. <source>Blood</source> <year>2010</year>; <volume>115</volume>: <fpage>706</fpage>–<lpage>712</lpage>.</citation></ref>
<ref id="bibr11-0961203313477898"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thachil</surname><given-names>J</given-names></name></person-group>. <article-title>Thrombotic thrombocytopenic purpura: Is there more than ADAMTS-13?</article-title> <source>J Thromb Haemost</source> <year>2007</year>; <volume>5</volume>: <fpage>634</fpage>–<lpage>635</lpage>.</citation></ref>
<ref id="bibr12-0961203313477898"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Musial</surname><given-names>J</given-names></name><name><surname>Swadzba</surname><given-names>J</given-names></name><name><surname>Szczeklik</surname><given-names>A</given-names></name></person-group>. <article-title>Adaptive mechanisms counterbalancing enhanced thrombinogenesis in antiphospholipid syndrome</article-title>. <source>Thromb Res</source> <year>1998</year>; <volume>90</volume>: <fpage>93</fpage>–<lpage>94</lpage>.</citation></ref>
<ref id="bibr13-0961203313477898"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamazaki</surname><given-names>M</given-names></name><name><surname>Asakura</surname><given-names>H</given-names></name><name><surname>Jokaji</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Plasma levels of lipoprotein(a) are elevated in patients with the antiphospholipid antibody syndrome</article-title>. <source>Thromb Haemost</source> <year>1994</year>; <volume>71</volume>: <fpage>424</fpage>–<lpage>427</lpage>.</citation></ref>
<ref id="bibr14-0961203313477898"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matsuyama</surname><given-names>T</given-names></name><name><surname>Kuwana</surname><given-names>M</given-names></name><name><surname>Matsumoto</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases</article-title>. <source>Thromb Haemost</source> <year>2009</year>; <volume>102</volume>: <fpage>371</fpage>–<lpage>378</lpage>.</citation></ref>
<ref id="bibr15-0961203313477898"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EM</given-names></name><name><surname>Cohen</surname><given-names>AS</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>The 1982 revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1982</year>; <volume>25</volume>: <fpage>1271</fpage>–<lpage>1277</lpage>.</citation></ref>
<ref id="bibr16-0961203313477898"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hochberg</surname><given-names>MC</given-names></name></person-group>. <article-title>Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1997</year>; <volume>40</volume>: <fpage>1725</fpage>–<lpage>1725</lpage>.</citation></ref>
<ref id="bibr17-0961203313477898"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soejima</surname><given-names>K</given-names></name></person-group>. <article-title>ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage</article-title>. <source>Blood</source> <year>2003</year>; <volume>102</volume>: <fpage>3232</fpage>–<lpage>3237</lpage>.</citation></ref>
<ref id="bibr18-0961203313477898"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bombardier</surname><given-names>C</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name><name><surname>Caron</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name></person-group>. <article-title>Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE</article-title>. <source>Arthritis Rheum</source> <year>1992</year>; <volume>35</volume>: <fpage>630</fpage>–<lpage>640</lpage>.</citation></ref>
<ref id="bibr19-0961203313477898"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>D</given-names></name><name><surname>Ginzler</surname><given-names>E</given-names></name><name><surname>Goldsmith</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1996</year>; <volume>39</volume>: <fpage>363</fpage>–<lpage>369</lpage>.</citation></ref>
<ref id="bibr20-0961203313477898"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cook</surname><given-names>RJ</given-names></name><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Pericak</surname><given-names>D</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name></person-group>. <article-title>Prediction of short term mortality in systemic lupus erythematosus with time dependent measures of disease activity</article-title>. <source>J Rheumatol</source> <year>2000</year>; <volume>27</volume>: <fpage>1892</fpage>–<lpage>1895</lpage>.</citation></ref>
<ref id="bibr21-0961203313477898"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Abrahamowicz</surname><given-names>M</given-names></name><name><surname>Fortin</surname><given-names>PR</given-names></name><name><surname>du Berger</surname><given-names>R</given-names></name><name><surname>Nayak</surname><given-names>V</given-names></name><name><surname>Neville</surname><given-names>C</given-names></name><name><surname>Liang</surname><given-names>MH</given-names></name></person-group>. <article-title>The relationship between disease activity and expert physician’s decision to start major treatment in active systemic lupus erythematosus: A decision aid for development of entry criteria for clinical trials</article-title>. <source>J Rheumatol</source> <year>1998</year>; <volume>25</volume>: <fpage>277</fpage>–<lpage>284</lpage>.</citation></ref>
<ref id="bibr22-0961203313477898"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bertsias</surname><given-names>G</given-names></name><name><surname>Ioannidis</surname><given-names>JPA</given-names></name><name><surname>Boletis</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics</article-title>. <source>Ann Rheum Dis</source> <year>2008</year>; <volume>67</volume>: <fpage>195</fpage>–<lpage>205</lpage>.</citation></ref>
<ref id="bibr23-0961203313477898"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Matrat</surname><given-names>A</given-names></name><name><surname>Veysseyre-Balter</surname><given-names>C</given-names></name><name><surname>Trolliet</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: Predictive value for renal flares</article-title>. <source>Lupus</source> <year>2011</year>; <volume>20</volume>: <fpage>28</fpage>–<lpage>34</lpage>.</citation></ref>
<ref id="bibr24-0961203313477898"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dayal</surname><given-names>NA</given-names></name><name><surname>Gordon</surname><given-names>C</given-names></name><name><surname>Tucker</surname><given-names>L</given-names></name><name><surname>Isenberg</surname><given-names>DA</given-names></name></person-group>. <article-title>The SLICC damage index: Past, present and future</article-title>. <source>Lupus</source> <year>2002</year>; <volume>11</volume>: <fpage>261</fpage>–<lpage>265</lpage>.</citation></ref>
<ref id="bibr25-0961203313477898"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miyakis</surname><given-names>S</given-names></name><name><surname>Lockshin</surname><given-names>MD</given-names></name><name><surname>Atsumi</surname><given-names>T</given-names></name><etal/></person-group>. <article-title>International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)</article-title>. <source>J Thromb Haemost</source> <year>2006</year>; <volume>4</volume>: <fpage>295</fpage>–<lpage>306</lpage>.</citation></ref>
<ref id="bibr26-0961203313477898"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Feys</surname><given-names>HB</given-names></name><name><surname>Dong</surname><given-names>N</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Ruan</surname><given-names>C</given-names></name></person-group>. <article-title>Alteration of ADAMTS13 antigen levels in patients with idiopathic thrombotic thrombocytopenic purpura, idiopathic thrombocytopenic purpura and systemic lupus erythematosus</article-title>. <source>Thromb Haemost</source> <year>2006</year>; <volume>95</volume>: <fpage>749</fpage>–<lpage>750</lpage>.</citation></ref>
<ref id="bibr27-0961203313477898"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rieger</surname><given-names>M</given-names></name><name><surname>Mannucci</surname><given-names>PM</given-names></name><name><surname>Kremer Hovinga</surname><given-names>JA</given-names></name><etal/></person-group>. <article-title>ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases</article-title>. <source>Blood</source> <year>2005</year>; <volume>106</volume>: <fpage>1262</fpage>–<lpage>1267</lpage>.</citation></ref>
<ref id="bibr28-0961203313477898"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mannucci</surname><given-names>PMVM</given-names></name><name><surname>Forza</surname><given-names>I</given-names></name><name><surname>Teresa</surname><given-names>CM</given-names></name><name><surname>Scorza</surname><given-names>R</given-names></name></person-group>. <article-title>Von Willebrand factor cleaving protease (ADAMTS-13) in 123 patients with connective tissue disases (systemic lupus erythematosus and systemic sclerosis)</article-title>. <source>Haematologica</source> <year>2003</year>; <volume>88</volume>: <fpage>914</fpage>–<lpage>918</lpage>.</citation></ref>
<ref id="bibr29-0961203313477898"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Austin</surname><given-names>SK</given-names></name><name><surname>Starke</surname><given-names>RD</given-names></name><name><surname>Lawrie</surname><given-names>AS</given-names></name><name><surname>Cohen</surname><given-names>H</given-names></name><name><surname>Machin</surname><given-names>SJ</given-names></name><name><surname>Mackie</surname><given-names>IJ</given-names></name></person-group>. <article-title>The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction</article-title>. <source>Br J Haematol</source> <year>2008</year>; <volume>141</volume>: <fpage>536</fpage>–<lpage>544</lpage>.</citation></ref>
<ref id="bibr30-0961203313477898"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>WJ</given-names></name><name><surname>Niiya</surname><given-names>M</given-names></name><name><surname>Zheng</surname><given-names>XW</given-names></name><name><surname>Shang</surname><given-names>DZ</given-names></name><name><surname>Zheng</surname><given-names>XL</given-names></name></person-group>. <article-title>Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells</article-title>. <source>J Thromb Haemost</source> <year>2008</year>; <volume>6</volume>: <fpage>1233</fpage>–<lpage>1235</lpage>.</citation></ref>
<ref id="bibr31-0961203313477898"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunt</surname><given-names>B</given-names></name></person-group>. <article-title>Microangiopathic haemolytic anaemias in systemic lupus erythematosus</article-title>. <source>Lupus</source> <year>2009</year>; <volume>18</volume>: <fpage>1028</fpage>–<lpage>1028</lpage>.</citation></ref>
</ref-list>
</back>
</article>